Court of Appeals for the Second Circuit January 30, 2007, No. 06-1583-CV (Leykin v. At & T Corp.)
Also known as
United States · · · 30-01-2007
SUMMARY ORDER
On consideration whereof, it is hereby ORDERED, ADJUDGED, and DECREED that the orders of the district court, dated September 17, 2008, August 9, 2004, and March 28, 2006 (as amended on June 28, 2006), be and they hereby are AFFIRMED.
Plaintiffs-appellants appeal the order dismissing their first amended complaint (“FAC”) and denying them leave to file second and third amended complaints. These three complaints all alleged, in pertinent part, that the defendants violated Sections 10(b), 14(a), and 20(a) of the Securities Exchange Act and the regulations promulgated thereunder, as well as committed common law fraud and breach of fiduciary in violation of Delaware law. See 15 U.S.C. §§ 78j(b), 78n, 78t(a); 17 C.F.R. §§ 240.10b, 240.14a-9. We assume the parties’ familiarity with the facts, the proceedings below, and the specification of issues on appeal.
The primary thrust of the plaintiffs’ complaint is that the AT & T defendants engaged in a secret scheme to convert At Home’s proprietary technology and that this scheme, as well as misrepresentations related to it, led to a decline in the price of At Home’s stock. To state a claim under § 10(b) and Rule 10b-5, plaintiffs must allege (1) a material misrepresentation (or omission), (2) scienter, (3) a connection with the purchase or sale of a security, (4) reliance, (5) economic loss, and (6) loss causation. Dura Pharms., Inc. v. Broudo, 544 U.S. 336, 341-42, 125 S.Ct. 1627, 161 L.Ed.2d 577 (2005). For substantially the reasons set forth by the district court, see Leykin v. AT & T Corp., 423 F.Supp.2d 229 (S.D.N.Y.2006), the plaintiffs here have failed to allege that the AT & T defendants’ conversion scheme was in connection with the purchase or sale of securities, see, e.g., Mutual Shares Corp. v. Genesco, Inc., 384 F.2d 540, 545-46 (2d Cir.1967), and that any misrepresentation associated with that scheme was the cause of plaintiffs’ loss under the standard set forth in Dura Pharmaceuticals, Inc. v.
Read the full text
This document is published by courtlistener.com.
Moonlit adds the citation network, article-level links and cross-references, which are available to search for free.
Sign in to Moonlit